1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29271
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDoocey R.en
dc.contributor.authorJohnston A.en
dc.contributor.authorArmytage T.en
dc.contributor.authorLee C.en
dc.contributor.authorCochrane T.en
dc.contributor.authorBerkhahn L.en
dc.contributor.authorWeinkove R.en
dc.contributor.authorHarrison S.J.en
dc.contributor.authorWebber N.en
dc.contributor.authorLee H.-P.en
dc.contributor.authorChapman S.en
dc.contributor.authorCampbell B.A.en
dc.contributor.authorGibbs S.D.J.en
dc.contributor.authorHamad N.en
dc.contributor.authorDi Ciaccio P.en
dc.contributor.authorMcCaughan G.en
dc.contributor.authorTrotman J.en
dc.contributor.authorHo P.J.en
dc.contributor.authorCheah C.Y.en
dc.contributor.authorGangatharan S.en
dc.contributor.authorWight J.en
dc.contributor.authorKu M.en
dc.contributor.authorQuach H.en
dc.contributor.authorGasiorowski R.en
dc.contributor.authorPolizzotto M.N.en
dc.contributor.authorPrince H.M.en
dc.contributor.authorMulligan S.en
dc.contributor.authorTam C.S.en
dc.contributor.authorGregory G.en
dc.contributor.authorHapgood G.en
dc.contributor.authorSpencer A.en
dc.contributor.authorDickinson M.en
dc.contributor.authorLatimer M.en
dc.date.accessioned2021-05-14T09:53:09Zen
dc.date.available2021-05-14T09:53:09Zen
dc.date.copyright2020en
dc.date.created20200620en
dc.date.issued2020-06-20en
dc.identifier.citationInternal Medicine Journal. 50 (6) (pp 667-679), 2020. Date of Publication: 01 Jun 2020.en
dc.identifier.issn1444-0903en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29271en
dc.description.abstractThe COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.Copyright © 2020 Royal Australasian College of Physiciansen
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishingen
dc.relation.ispartofInternal Medicine Journalen
dc.subject.meshrituximab-
dc.subject.meshvincristine-
dc.subject.meshvincristine sulfate-
dc.subject.meshbcl2 gene-
dc.subject.meshBCL6 gene-
dc.subject.meshgene rearrangement-
dc.subject.meshHerpes simplex virus-
dc.subject.meshlymphoma-
dc.subject.meshmaintenance therapy-
dc.subject.meshmantle cell lymphoma-
dc.subject.meshmultiple myeloma-
dc.subject.meshmyeloma-
dc.subject.meshNew Zealand-
dc.subject.meshoncogene myc-
dc.subject.meshpandemic-
dc.subject.meshpatient attitude-
dc.subject.meshsalvage therapy-
dc.subject.meshscreening test-
dc.subject.meshtelehealth-
dc.subject.meshvaccination-
dc.subject.meshvirus shedding-
dc.subject.meshvirus transmission-
dc.subject.meshcyclophosphamide-
dc.subject.meshcytarabine-
dc.subject.meshdoxorubicin-
dc.subject.meshetoposide-
dc.subject.meshgrowth factor-
dc.subject.meshibrutinib-
dc.subject.meshifosfamide-
dc.subject.meshimmunoglobulin-
dc.subject.meshmethotrexate-
dc.subject.meshMyc protein-
dc.subject.meshprednisolone-
dc.subject.meshprotein bcl 2-
dc.subject.meshprotein bcl 6-
dc.subject.meshrituximab-
dc.subject.meshvenetoclax-
dc.subject.meshvincristine-
dc.subject.meshAL amyloidosis-
dc.subject.meshantifungal therapy-
dc.subject.meshAustralian-
dc.subject.meshautologous stem cell transplantation-
dc.subject.meshB cell lymphoma-
dc.subject.meshBurkitt lymphoma-
dc.subject.meshcancer grading-
dc.subject.meshcancer immunotherapy-
dc.subject.meshcancer radiotherapy-
dc.subject.meshcancer recurrence-
dc.subject.meshchronic lymphatic leukemia-
dc.subject.meshcoronavirus disease 2019-
dc.subject.meshdiagnostic test-
dc.subject.meshdiffuse large B cell lymphoma-
dc.subject.meshfollicular lymphoma-
dc.titleAustralian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.en
dc.typeArticleen
dc.identifier.affiliationHaematology-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/imj.14859-
dc.publisher.placeAustraliaen
dc.identifier.pubmedid32415723 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32415723]en
dc.identifier.source2004934064en
dc.identifier.institution(Di Ciaccio, McCaughan, Polizzotto, Hamad) Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia (Di Ciaccio, McCaughan, Polizzotto, Hamad) University of New South Wales, Sydney, NSW, Australia (McCaughan, Trotman, Ho, Gasiorowski, Mulligan, Hamad) University of Sydney, Sydney, NSW, Australia (Trotman, Gasiorowski) Department of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia (Ho) Department of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia (Cheah) Department of Haematology, Pathwest Laboratory Medicine, Perth, WA, Australia (Cheah, Gangatharan) University of Western Australia, Perth, WA, Australia (Gangatharan) Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia (Wight) Townsville University Hospital, Townsville, QLD, Australia (Wight, Ku, Quach, Prince, Tam, Spencer, Dickinson, Harrison, Campbell) University of Melbourne, Melbourne, VIC, Australia (Ku, Quach, Tam) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Polizzotto) The Kirby Institute, University of New South Wales, Sydney, NSW, Australia (Prince, Tam, Dickinson, Harrison) Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Prince) Department of Haematology, Epworth Healthcare, Melbourne, VIC, Australia (Mulligan) Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia (Gregory) Department of Haematology, Monash Health, Melbourne, VIC, Australia (Hapgood) Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia (Spencer) Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia (Latimer) Department of Haematology, Canberra Hospital, Canberra, ACT, Australia (Johnston) Department of Haematology, The Royal Hobart Hospital, Hobart, TAS, Australia (Johnston) University of Tasmania, Hobart, TAS, Australia (Armytage) Department of Haematology, Gosford Hospital, Gosford, NSW, Australia (Lee) Department of Haematology, Queen Elizabeth Hospital, Adelaide, SA, Australia (Cochrane) Department of Haematology, Gold Coast University Hospital, Southport, QLD, Australia (Cochrane) Griffith University, Brisbane, QLD, Australia (Berkhahn, Doocey) Department of Haematology, The Auckland City Hospital, Auckland, New Zealand (Berkhahn) University of Auckland, Auckland, New Zealand (Weinkove) Department of Haematology, Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand (Weinkove) Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand (Webber) Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia (Lee) Department of Haematology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, SA, Australia (Chapman) Department of Infectious Diseases, St Vincent's Hospital, Sydney, NSW, Australia (Campbell) Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Gibbs) Department of Haematology, Eastern Health, Melbourne, VIC, Australia (Gibbs) Monash University, Melbourne, VIC, Australiaen
dc.description.addressN. Hamad, Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia. E-mail: nada.hamad@svha.org.au N. Hamad, University of New South Wales, Sydney, NSW, Australia. E-mail: nada.hamad@svha.org.au N. Hamad, University of Sydney, Sydney, NSW, Australia. E-mail: nada.hamad@svha.org.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordschronic lymphocytic leukaemia COVID-19 lymphoma myelomaen
dc.identifier.authoremailHamad N.; nada.hamad@svha.org.auen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

40
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.